{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:10:32Z","timestamp":1792041032375,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":201,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"F. Hoffmann-La Roche, Basel, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This first-in-human study evaluated EGFRvIII\u2005\u00d7\u2005CD3 TCB, a novel T cell bispecific antibody, in patients with newly diagnosed EGFRvIII-positive glioblastoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with newly diagnosed glioblastoma received escalating doses of EGFRvIII\u2005\u00d7\u2005CD3 TCB following chemoradiation. The primary objectives were to evaluate safety\/tolerability and define the maximum tolerated dose (MTD); secondary objectives included pharmacokinetics (PK), immunogenicity, pharmacodynamics, and clinical activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-six patients were enrolled, 32 with unmethylated and 4 with methylated MGMT promoter. EGFRvIII\u2005\u00d7\u2005CD3 TCB doses ranged from 0.004 to 10 mg Q3W, administered either on a flat or step-up dose schedule. One DLT occurred (grade 3 seizure). The MTD was not reached. Most adverse events (AEs) were of grade 1-2 severity, with headache being the most common treatment-related AE (22%). EGFRvIII\u2005\u00d7\u2005CD3 TCB showed dose-proportional PK in serum and cerebrospinal fluid (CSF), with a CSF\/serum ratio of 0.08. At the highest dose tested, 10 mg Q3W, maximum serum concentrations remained 6-fold below the lower boundary of the predicted anticipated therapeutic dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The administration of EGFRvIII\u2005\u00d7\u2005CD3 TCB in a maintenance setting, following standard of care treatment, was safe and well tolerated up to the highest tested dose of 10 mg Q3W. However, evidence of efficacy was not observed at the evaluated doses, suggesting that a study of higher dose levels may be warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf160","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:14:52Z","timestamp":1752585292000},"source":"Crossref","is-referenced-by-count":1,"title":["First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-2037","authenticated-orcid":false,"given":"James R","family":"Whittle","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-9003","authenticated-orcid":false,"given":"Kristoffer","family":"Rohrberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospitalet, University Hospital of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[{"name":"Oncology, Clinica Universidad de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Castanon","sequence":"additional","affiliation":[{"name":"Oncology, Clinica Universidad de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology and Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center , New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"Van Linde","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam University Medical Center, location VU Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-7483","authenticated-orcid":false,"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles , California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Reardon","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ronald Reagan UCLA Medical Center, University of California, Los Angeles , California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Wick","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inja","family":"Waldhauer","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Roche Innovation Center Zurich , Schlieren ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Henkel","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Romagnoli","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Wolowski","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuva","family":"Dey","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heil","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Heichinger","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Flinn","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Gou","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Smith","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Prince","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Derks","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Roller","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schiff","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Schneider","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Clinical Development Oncology, Roche Innovation Center Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Medicine, Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"2025082007465196900_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20142020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro-Oncology."},{"issue":"10","key":"2025082007465196900_CIT0002","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme\u2013literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"2025082007465196900_CIT0003","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"1","key":"2025082007465196900_CIT0004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-019-03334-5","article-title":"Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study","volume":"146","author":"Pinson","year":"2020","journal-title":"J Neurooncol."},{"issue":"1","key":"2025082007465196900_CIT0005","first-page":"vdaa082","article-title":"Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Alnahhas","year":"2020","journal-title":"Neurooncol. Adv.."},{"issue":"10","key":"2025082007465196900_CIT0006","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"17","key":"2025082007465196900_CIT0007","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.3390\/cancers15174279","article-title":"Recurrent Glioblastoma: A Review of the Treatment Options","volume":"15","author":"Vaz-Salgado","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5998","key":"2025082007465196900_CIT0008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/313144a0","article-title":"Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin","volume":"313","author":"Libermann","year":"1985","journal-title":"Nature."},{"issue":"3","key":"2025082007465196900_CIT0009","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1042\/bj3240855","article-title":"Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)","volume":"324 ( Pt 3)","author":"Chu","year":"1997","journal-title":"Biochem J."},{"issue":"10","key":"2025082007465196900_CIT0010","first-page":"1251","article-title":"Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene","volume":"6","author":"Batra","year":"1995","journal-title":"Cell Growth Differ."},{"issue":"4","key":"2025082007465196900_CIT0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.mcn.2003.09.011","article-title":"Constitutive EGFR signaling confers a motile phenotype to neural stem cells","volume":"24","author":"Boockvar","year":"2003","journal-title":"Mol Cell Neurosci."},{"issue":"3","key":"2025082007465196900_CIT0012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2004.07.004","article-title":"Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance","volume":"72","author":"Lammering","year":"2004","journal-title":"Radiother Oncol"},{"issue":"2","key":"2025082007465196900_CIT0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-006-9220-3","article-title":"Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R\u03b12, gp100 and TRP-2 for immunotherapy","volume":"81","author":"Saikali","year":"2006","journal-title":"J Neurooncol."},{"issue":"6","key":"2025082007465196900_CIT0014","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro Oncol"},{"issue":"4","key":"2025082007465196900_CIT0015","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"Eur J Cancer."},{"issue":"5","key":"2025082007465196900_CIT0016","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med."},{"issue":"2","key":"2025082007465196900_CIT0017","doi-asserted-by":"crossref","first-page":"e000966","DOI":"10.1136\/jitc-2020-000966","article-title":"T-cell agonists in cancer immunotherapy","volume":"8","author":"Choi","year":"2020","journal-title":"J ImmunoTher Cancer."},{"issue":"10","key":"2025082007465196900_CIT0018","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends in Cancer"},{"issue":"4","key":"2025082007465196900_CIT0019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov."},{"issue":"10","key":"2025082007465196900_CIT0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-22-0201","article-title":"A novel EGFRvIII T-cell bispecific antibody for the treatment of glioblastoma","volume":"21","author":"Iurlaro","year":"2022","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"2025082007465196900_CIT0021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"2025082007465196900_CIT0022","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group","volume":"28","author":"Wen","year":"2010","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"2025082007465196900_CIT0023","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.15350","article-title":"Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies","volume":"158","author":"Schmid","year":"2021","journal-title":"J Neurochem."},{"issue":"4","key":"2025082007465196900_CIT0024","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-04-1737","article-title":"Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients","volume":"11","author":"Heimberger","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2025082007465196900_CIT0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1593\/neo.111338","article-title":"Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited","volume":"13","author":"Montano","year":"2011","journal-title":"Neoplasia"},{"issue":"22","key":"2025082007465196900_CIT0026","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2025082007465196900_CIT0027","doi-asserted-by":"crossref","first-page":"983","DOI":"10.21873\/anticanres.14852","article-title":"Epidermal Growth Factor Receptor and its Oncogenic EGFRvIII Variant in Benign and Malignant Brain Tumors","volume":"41","author":"Kielbus","year":"2021","journal-title":"Anticancer Res."},{"issue":"2","key":"2025082007465196900_CIT0028","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1158\/1078-0432.CCR-07-1966","article-title":"Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples","volume":"14","author":"Yoshimoto","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025082007465196900_CIT0029","doi-asserted-by":"crossref","first-page":"101756","DOI":"10.1016\/j.inat.2023.101756","article-title":"The clinical progression of patients with glioblastoma","volume":"32","author":"Hansen","year":"2023","journal-title":"Interdisciplinary Neurosurgery"},{"issue":"1","key":"2025082007465196900_CIT0030","doi-asserted-by":"crossref","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"2025082007465196900_CIT0031","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer."},{"issue":"22","key":"2025082007465196900_CIT0032","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med."},{"issue":"13","key":"2025082007465196900_CIT0033","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2025082007465196900_CIT0034","doi-asserted-by":"crossref","first-page":"e55532","DOI":"10.15252\/embr.202255532","article-title":"T cell-dependent bispecific antibodies alter organ-specific endothelial cell\u2013T cell interaction","volume":"24","author":"Himmels","year":"2023","journal-title":"EMBO Rep."},{"issue":"12","key":"2025082007465196900_CIT0035","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.3390\/ijms22126442","article-title":"Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives","volume":"22","author":"Kouhi","year":"2021","journal-title":"Int J Mol Sci ."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf160\/63808223\/vdaf160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf160\/63808223\/vdaf160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf160\/63808223\/vdaf160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T11:47:04Z","timestamp":1755690424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf160\/8209511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf160","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf160"}}